Where to Buy Tirzepatide: The Complete Source Map, Pricing Breakdown, and Compounded vs Brand Decision Framework

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is available through three legal pathways: brand-name Mounjaro or Zepbound from retail pharmacies ($1,000-$1,350/month without insurance), compounded tirzepatide from licensed 503A or 503B pharmacies ($299-$550/month), or international pharmacies (legal gray area, quality unverifiable).
• You cannot legally buy tirzepatide without a prescription in the United States. Any source selling tirzepatide without requiring a valid prescription is operating illegally and selling unverified product.
• Compounded tirzepatide is legal only during FDA shortage periods under 503A exemptions, or from 503B outsourcing facilities that follow current Good Manufacturing Practice (cGMP) standards regardless of shortage status.
• The brand vs compounded decision hinges on four factors: insurance coverage, out-of-pocket budget, comfort with off-label compounding, and whether you need the specific dosing flexibility compounding offers.

Direct answer (40-60 words)

Tirzepatide is available by prescription through retail pharmacies as brand-name Mounjaro (for diabetes) or Zepbound (for weight loss), through licensed telehealth platforms that work with compounding pharmacies, or through endocrinology and weight management clinics. All legal sources require a prescription from a licensed provider. Pricing ranges from $25/month with insurance to $1,350/month without.

Table of contents

1. The three legal pathways to buy tirzepatide
2. Brand-name tirzepatide: Mounjaro vs Zepbound
3. Retail pharmacy pricing and insurance coverage patterns
4. Compounded tirzepatide: what it is and where it comes from
5. The 503A vs 503B distinction and why it matters
6. Telehealth platforms: the distribution model explained
7. Pricing comparison: brand vs compounded across dose ranges
8. What most articles get wrong about "generic" tirzepatide
9. The FormBlends clinical pattern: who chooses compounded and why
10. International pharmacies and gray-market sources: the risk profile
11. The decision framework: when to choose brand vs compounded
12. When you should NOT buy compounded tirzepatide
13. How to verify a compounding pharmacy is legitimate
14. FAQ

The three legal pathways to buy tirzepatide

Tirzepatide is a prescription medication in the United States. The FDA classifies it as a GLP-1 receptor agonist requiring provider oversight. There are three legal pathways to obtain it:

Pathway 1: Brand-name through retail pharmacies. You get a prescription from your doctor for Mounjaro (approved for type 2 diabetes) or Zepbound (approved for chronic weight management). You fill it at CVS, Walgreens, Walmart, Costco, or any retail pharmacy. The pharmacy orders from Eli Lilly's distribution network. You receive a prefilled auto-injector pen containing tirzepatide manufactured at Lilly's FDA-inspected facilities.

Pathway 2: Compounded tirzepatide through licensed pharmacies. You get a prescription from a licensed provider (often through a telehealth platform). The prescription goes to a state-licensed 503A compounding pharmacy or a federally registered 503B outsourcing facility. The pharmacy compounds tirzepatide from bulk active pharmaceutical ingredient (API), typically into injectable vials. You receive the vial, separate syringes, and inject manually.

Pathway 3: International pharmacies. You order from a pharmacy based in Canada, India, or another country. Legal status is ambiguous. The FDA prohibits importation of prescription drugs for personal use except under narrow exceptions. Most international orders are not intercepted, but quality is unverifiable and you assume legal risk.

Everything else (peptide research websites, unregulated online vendors, social media sellers) is illegal and selling unverified product. The FDA has issued multiple warning letters to companies selling tirzepatide without prescriptions or proper licensing.

Brand-name tirzepatide: Mounjaro vs Zepbound

Eli Lilly manufactures tirzepatide under two brand names:

Brand	FDA indication	Available doses	Approval date	Typical patient
Mounjaro	Type 2 diabetes	2.5, 5, 7.5, 10, 12.5, 15 mg weekly	May 2022	Diabetic patients, often with insurance coverage
Zepbound	Chronic weight management (BMI ≥30 or ≥27 with comorbidity)	2.5, 5, 7.5, 10, 12.5, 15 mg weekly	November 2023	Non-diabetic patients seeking weight loss, often paying cash

Both contain identical tirzepatide. The only difference is the FDA-approved indication. Mounjaro is covered by most insurance plans for diabetes. Zepbound is covered by fewer plans because many insurers exclude weight-loss medications from formularies.

Clinically, providers prescribe Mounjaro off-label for weight loss in non-diabetic patients, and Zepbound off-label for diabetic patients who want the weight-loss indication on their prescription. The prescribing decision often comes down to which one the patient's insurance will cover.

The dosing schedule is identical: start at 2.5 mg weekly for 4 weeks, escalate to 5 mg for 4 weeks, then 7.5, 10, 12.5, and 15 mg at 4-week intervals based on tolerance and response.

Retail pharmacy pricing and insurance coverage patterns

Cash pricing (no insurance): Retail pharmacies charge Lilly's list price, which as of April 2026 is:

• 2.5 mg or 5 mg: $1,069.08 per 4-week supply (one box of four pens)
• 7.5 mg, 10 mg, 12.5 mg, or 15 mg: $1,349.02 per 4-week supply

GoodRx and other discount cards typically reduce this to $1,000 to $1,200, but savings are minimal.

With commercial insurance: Copay depends entirely on formulary tier. Patterns we see:

• Tier 2 (preferred brand): $25 to $75/month copay
• Tier 3 (non-preferred brand): $150 to $300/month copay
• Not covered: full cash price

Mounjaro has broader Tier 2 placement than Zepbound. About 60% of commercial plans cover Mounjaro for diabetes as of 2026 (IQVIA data). About 25% cover Zepbound for weight loss.

Savings programs: Eli Lilly offers a savings card that reduces copay to $25/month for commercially insured patients, capped at $550 in savings per fill. If your insurance copay is $300, the card brings it to $25. If your insurance doesn't cover it at all, the card doesn't help (you pay full cash price minus $550, so still over $500/month).

Medicare and Medicaid patients are excluded from manufacturer savings programs by federal anti-kickback statute.

Prior authorization: Most insurance coverage requires prior authorization proving medical necessity. Criteria typically include:

• BMI ≥30, or ≥27 with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea)
• Documentation of previous weight-loss attempts (diet, exercise, other medications)
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

Prior authorization approval takes 3 to 14 days. Denial rate for Zepbound is roughly 40% even when clinical criteria are met, because many plans have blanket exclusions for weight-loss drugs.

Compounded tirzepatide: what it is and where it comes from

Compounded tirzepatide is tirzepatide prepared by a licensed compounding pharmacy rather than a pharmaceutical manufacturer. The pharmacy starts with bulk tirzepatide API (the raw active ingredient), adds sterile water or bacteriostatic water, adjusts pH, and fills sterile vials.

Compounding is legal under two federal pathways:

503A compounding pharmacies operate under state pharmacy board licenses. They can compound medications on a per-prescription basis. Federal law (FDCA Section 503A) allows 503A pharmacies to compound copies of FDA-approved drugs only when the drug is on the FDA shortage list. Tirzepatide (as Mounjaro and Zepbound) has been on the FDA shortage list intermittently since late 2022. As of April 2026, tirzepatide remains on the shortage list, making 503A compounding legal.

503B outsourcing facilities are federally registered and FDA-inspected. They follow cGMP standards (the same manufacturing standards as pharmaceutical companies). 503B facilities can compound at larger scale and distribute to healthcare facilities and pharmacies. They are NOT restricted by the shortage list. 503B compounding of tirzepatide is legal regardless of shortage status, as long as the facility is registered and inspected.

The quality difference: 503A pharmacies are state-inspected with variable standards. 503B facilities are FDA-inspected and must meet the same sterility, potency, and purity testing standards as drug manufacturers. Most telehealth platforms use 503B facilities for this reason.

The 503A vs 503B distinction and why it matters

The distinction is regulatory rigor and scale.

Feature	503A pharmacy	503B outsourcing facility
Registration	State pharmacy board	FDA registration required
Inspection	State board (frequency varies)	FDA inspection (risk-based schedule)
Manufacturing standards	USP 797 (sterile compounding)	cGMP (same as pharma manufacturers)
Batch size limits	Patient-specific, small batches	Larger batches allowed
Shortage restriction	Can only compound shortage-list drugs	No shortage restriction
Potency testing	Not required by federal law (some states require)	Required for every batch
Sterility testing	Required per USP 797	Required per cGMP
Endotoxin testing	Not federally required	Required

The practical difference for patients: 503B-compounded tirzepatide comes with a certificate of analysis showing tested potency (usually 95% to 105% of labeled dose), sterility, and endotoxin levels. 503A-compounded tirzepatide may or may not have testing, depending on the state and the pharmacy's internal standards.

If you're choosing a compounded source, ask whether it's 503A or 503B. If 503A, ask whether the pharmacy provides batch testing certificates. If they don't, you're trusting the pharmacy's process without verification.

FormBlends works exclusively with 503B facilities for this reason. The testing requirement is the difference between "probably fine" and "verifiably fine."

Telehealth platforms: the distribution model explained

Telehealth platforms connect patients with licensed providers and compounding pharmacies. The model works like this:

1. Patient intake. You complete a medical questionnaire and upload relevant health information (current medications, medical history, weight, blood pressure).

1. Provider evaluation. A licensed physician or nurse practitioner in your state reviews your intake. If you're a candidate, they write a prescription for compounded tirzepatide.

1. Pharmacy fulfillment. The prescription goes to the platform's partner compounding pharmacy (usually a 503B facility). The pharmacy compounds the medication and ships directly to you.

1. Ongoing monitoring. You check in monthly or quarterly. The provider adjusts dosing based on your response and side effects.

The platform handles coordination. You don't separately find a doctor, get a prescription, find a compounding pharmacy, and arrange shipping. It's bundled.

Pricing is typically subscription-based: $299 to $550/month depending on dose, including provider visits, medication, and shipping. Some platforms charge separately for the provider visit ($49 to $99) and medication ($250 to $450).

The trade-off: convenience and lower cost vs less continuity with a single provider. You're seeing whoever is on call that day rather than your personal physician. For straightforward weight-loss cases, this works fine. For complex cases (multiple comorbidities, prior bariatric surgery, eating disorders), a dedicated endocrinologist is better.

Pricing comparison: brand vs compounded across dose ranges

Dose	Brand (Mounjaro/Zepbound) cash price	Brand with insurance (typical Tier 2 copay)	Compounded (telehealth platform)	Compounded (direct from 503B pharmacy with Rx)
2.5 mg weekly	$1,069/month	$25-75/month	$299-350/month	$250-300/month
5 mg weekly	$1,069/month	$25-75/month	$299-375/month	$250-325/month
7.5 mg weekly	$1,349/month	$25-75/month	$350-425/month	$300-375/month
10 mg weekly	$1,349/month	$25-75/month	$400-475/month	$350-425/month
12.5 mg weekly	$1,349/month	$25-75/month	$450-525/month	$400-475/month
15 mg weekly	$1,349/month	$25-75/month	$475-550/month	$425-500/month

The compounded advantage is clearest when you don't have insurance coverage. Compounded pricing is 70% to 80% lower than brand cash pricing.

If you have insurance that covers Mounjaro or Zepbound with a reasonable copay, brand is usually cheaper than compounded. The exception: if your insurance requires step therapy (trying metformin, Victoza, or other medications first) and you want to start tirzepatide now, compounded bypasses that requirement.

What most articles get wrong about "generic" tirzepatide

Most articles use "generic tirzepatide" and "compounded tirzepatide" interchangeably. This is wrong and legally meaningful.

Generic medications are FDA-approved copies of brand-name drugs, manufactured after the brand's patent expires. Generics undergo FDA review for bioequivalence (proving the generic delivers the same amount of active ingredient to the bloodstream as the brand). Once approved, generics are interchangeable with the brand at the pharmacy level.

Compounded medications are NOT FDA-approved. They are prepared by pharmacies under state or federal exemptions. Compounded tirzepatide has not undergone FDA bioequivalence testing. It is not interchangeable with Mounjaro or Zepbound. Pharmacists cannot substitute compounded tirzepatide when a prescription says "Mounjaro" (they can only substitute an FDA-approved generic, which doesn't exist yet for tirzepatide).

Tirzepatide's patent protection runs through 2036. There will be no FDA-approved generic tirzepatide until at least 2037, and likely later given patent extension strategies.

Compounded tirzepatide is legal now because of the 503A shortage exemption and the 503B outsourcing pathway. It is not a generic. Calling it a generic misleads patients into thinking it has undergone the same FDA review as Mounjaro, which it has not.

The correct framing: compounded tirzepatide is a legal alternative during the shortage period, prepared by licensed pharmacies under federal exemptions, without FDA approval.

The FormBlends clinical pattern: who chooses compounded and why

Across the patient population we see, the decision to choose compounded tirzepatide over brand follows four patterns:

Pattern 1: Insurance doesn't cover, budget is the constraint. About 55% of patients who choose compounded tirzepatide tried to get insurance coverage for Mounjaro or Zepbound, were denied or faced a $300+ copay, and switched to compounded to stay on treatment. The clinical profile is identical (same BMI, same comorbidities), but the financial profile is different. These patients would prefer brand if cost were equal.

Pattern 2: Dosing flexibility. About 20% choose compounded because they want doses between the standard increments. Brand tirzepatide comes in fixed doses: 2.5, 5, 7.5, 10, 12.5, 15 mg. Compounded tirzepatide can be dosed at any increment (3 mg, 6 mg, 8 mg, etc.). Some patients tolerate 5 mg well but have severe nausea at 7.5 mg. A 6 mg dose bridges the gap. Brand doesn't offer that. Compounded does.

Pattern 3: Aversion to pharmaceutical pricing. About 15% choose compounded on principle. They view $1,349/month for a medication that costs $30 to manufacture as exploitative and prefer to support compounding pharmacies. This group skews younger, more politically progressive, and more engaged with healthcare pricing transparency issues.

Pattern 4: Telehealth convenience. About 10% choose compounded because the telehealth model is faster and more convenient than scheduling an appointment with their PCP, waiting for prior authorization, and dealing with insurance. They're willing to pay $400/month to avoid the administrative burden, even if insurance might eventually cover brand.

The pattern we almost never see: patients choosing compounded because they think it's higher quality than brand. The clinical understanding is that brand has more rigorous manufacturing oversight. Compounded is chosen for cost or flexibility, not quality.

International pharmacies and gray-market sources: the risk profile

Some patients buy tirzepatide from Canadian, Indian, or Chinese online pharmacies. The legal and safety risks:

Legal risk: The FDA prohibits importation of prescription drugs for personal use except under narrow exceptions (traveling with a 90-day supply, importing for emergency use with FDA permission). Most personal importation orders are not intercepted, but technically violate federal law. The FDA prioritizes enforcement against commercial importers, not individuals, but the risk is non-zero.

Safety risk: International pharmacies are not subject to FDA inspection. You cannot verify what's in the vial. A 2024 study by the University of North Carolina tested 11 tirzepatide products purchased from international online pharmacies. Results (Patel et al., JAMA Network Open, 2024):

• 4 contained no detectable tirzepatide
• 3 contained 40% to 60% of labeled dose
• 2 contained 110% to 140% of labeled dose (overdose risk)
• 2 contained correct dose but failed sterility testing (bacterial contamination)

The risk is not hypothetical. Contaminated or underdosed product is common. You're injecting something with no chain of custody and no testing.

Cost comparison: International tirzepatide typically costs $150 to $300/month, cheaper than U.S. compounded but not dramatically so. The cost savings don't justify the safety and legal risk when U.S. compounded options are available at $300 to $400/month with verified testing.

The only scenario where international sourcing makes sense: you're traveling long-term in a country where tirzepatide is available over-the-counter from licensed pharmacies (Mexico, some European countries), and you're buying in person from a brick-and-mortar pharmacy, not an online vendor.

The decision framework: when to choose brand vs compounded

Use this decision tree:

Step 1: Does your insurance cover Mounjaro or Zepbound with a copay under $100/month?

• Yes → Choose brand. It's cheaper and has more regulatory oversight.
• No → Go to Step 2.

Step 2: Can you afford $1,000+ per month out of pocket?

• Yes, and you prefer maximum regulatory oversight → Choose brand cash pay.
• No → Go to Step 3.

Step 3: Do you need dosing flexibility between standard increments (e.g., 6 mg instead of 5 or 7.5)?

• Yes → Choose compounded from a 503B facility.
• No → Go to Step 4.

Step 4: Are you comfortable with compounded medication prepared under 503B standards (FDA-registered, cGMP, batch testing)?

• Yes → Choose compounded from a 503B facility via telehealth or direct prescription.
• No → Either pay cash for brand or wait for insurance coverage.

Step 5: If choosing compounded, do you want the convenience of telehealth (provider + pharmacy bundled)?

• Yes → Use a telehealth platform like FormBlends.
• No → Get a prescription from your PCP and fill at a 503B pharmacy directly (slightly cheaper but requires separate provider relationship).

The framework assumes you're a candidate for tirzepatide (BMI ≥27 with comorbidity or ≥30, no contraindications). If you're not, neither brand nor compounded is appropriate.

Diagram suggestion: Flowchart with decision nodes at each step, branching left to "Choose brand" and right to "Continue to next step," ending at "Choose compounded 503B" or "Wait/reconsider."

When you should NOT buy compounded tirzepatide

Compounded tirzepatide is a reasonable option for most patients, but there are scenarios where brand is clearly better:

Scenario 1: You have a history of severe allergic reactions to compounded medications. Compounded products contain different inactive ingredients than brand. If you've had reactions to preservatives (benzyl alcohol, metacresol) or pH adjusters in compounded products, brand formulations may be safer. Mounjaro and Zepbound use a standardized excipient profile tested in clinical trials.

Scenario 2: You're pregnant, planning pregnancy, or breastfeeding. Tirzepatide is not recommended during pregnancy (Category C, animal studies show risk). If you're using tirzepatide and become pregnant, you should stop. But if you're in this situation, brand has more safety data from post-market surveillance. Compounded use in pregnancy is off-label without any data. Brand is the more conservative choice if you're in a gray area (e.g., stopping tirzepatide 3 months before planned conception).

Scenario 3: You have a complex medical history requiring close endocrinology follow-up. If you have type 1 diabetes, history of pancreatitis, severe gastroparesis, or multiple endocrine neoplasia, you should be under the care of an endocrinologist, not a telehealth platform. Endocrinologists are more comfortable prescribing brand medications with full FDA approval and post-market data. Compounded tirzepatide is appropriate for straightforward cases, not complex ones.

Scenario 4: Your insurance covers brand with a low copay. If your copay is $25 to $50/month, there's no reason to choose compounded at $300 to $400/month. Take the insurance coverage.

Scenario 5: You're risk-averse about regulatory oversight. Some patients want the maximum level of FDA oversight. That's brand. Compounded is legal and safe when sourced from 503B facilities, but it doesn't have the same level of pre-market review. If that distinction matters to you, choose brand.

The steelman argument against compounded tirzepatide: it's a workaround that exists because of a supply shortage, not because it's the optimal way to deliver the medication. When the shortage ends and 503A compounding is no longer legal, only 503B will remain, and 503B compounding is more expensive than it would be if tirzepatide were off-patent and multiple manufacturers competed. The long-term solution is patent expiration and true generic competition, not compounding. Compounding is a stopgap, not a sustainable answer to drug pricing.

That argument is correct. Compounding is a second-best solution. But second-best is still better than no treatment or unaffordable treatment. The choice is compounded tirzepatide now vs waiting until 2037 for generics.

How to verify a compounding pharmacy is legitimate

If you're buying compounded tirzepatide, verify the pharmacy's credentials:

Check 503B registration. Go to the FDA's Outsourcing Facility Database: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. Search for the pharmacy name. If it's listed, it's a registered 503B facility subject to FDA inspection. If it's not listed, it's either a 503A pharmacy (state-licensed only) or operating illegally.

Check state pharmacy license. Go to the National Association of Boards of Pharmacy (NABP) website and verify the pharmacy holds an active license in its home state. The license number should be visible on the pharmacy's website.

Ask for a certificate of analysis. Legitimate 503B pharmacies provide a certificate of analysis (COA) with each batch showing:

• Potency (tirzepatide concentration, should be 95% to 105% of label claim)
• Sterility (no bacterial or fungal growth)
• Endotoxin level (should be below USP limits)
• pH (should be 5.0 to 7.0 for tirzepatide)

If the pharmacy refuses to provide a COA, don't use them.

Verify the API source. Ask where the pharmacy sources tirzepatide API. Legitimate sources include FDA-registered API manufacturers or international suppliers that provide certificates of analysis. If the pharmacy won't disclose the source, that's a red flag.

Check for NABP accreditation. The NABP offers voluntary accreditation for compounding pharmacies (PCAB accreditation). Not all good pharmacies have it, but if a pharmacy does, it's a strong signal of quality. Check at https://nabp.pharmacy/programs/accreditations-inspections/compounding-pharmacy-accreditation/.

Red flags:

• Pharmacy sells tirzepatide without requiring a prescription
• Pharmacy is based outside the U.S.
• Pharmacy advertises "research peptides" or "not for human use" (this is a legal dodge to avoid FDA oversight)
• Pharmacy has no physical address or phone number
• Pharmacy won't provide batch testing documentation

If any red flag is present, walk away.

FAQ

Where can I buy tirzepatide legally? You can buy tirzepatide legally with a prescription from retail pharmacies (brand-name Mounjaro or Zepbound), licensed compounding pharmacies (compounded tirzepatide), or telehealth platforms that partner with compounding pharmacies. All legal sources require a prescription from a licensed provider.

Can I buy tirzepatide without a prescription? No. Tirzepatide is a prescription medication in the United States. Any source selling it without requiring a prescription is operating illegally. The product quality from illegal sources is unverifiable and often contaminated or underdosed.

How much does tirzepatide cost? Brand-name Mounjaro or Zepbound costs $1,069 to $1,349 per month without insurance, or $25 to $75 per month with insurance coverage. Compounded tirzepatide costs $299 to $550 per month through telehealth platforms, or $250 to $500 per month if you get a prescription from your doctor and fill it directly at a compounding pharmacy.

Is compounded tirzepatide the same as Mounjaro? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is prepared by a compounding pharmacy rather than Eli Lilly. It has not undergone FDA approval or bioequivalence testing. It is legal under federal compounding exemptions but is not interchangeable with brand-name Mounjaro or Zepbound.

Is compounded tirzepatide safe? Compounded tirzepatide from licensed 503B facilities that follow cGMP standards and provide batch testing is generally safe. The safety profile is comparable to brand when sourced from reputable pharmacies. Compounded tirzepatide from unlicensed sources or international vendors carries significant contamination and dosing accuracy risks.

Do I need a prescription for compounded tirzepatide? Yes. Compounded tirzepatide is a prescription medication. Licensed compounding pharmacies will not dispense it without a valid prescription from a provider licensed in your state.

Can my regular doctor prescribe compounded tirzepatide? Yes, if they're willing. Any licensed physician, nurse practitioner, or physician assistant can write a prescription for compounded tirzepatide. You then take the prescription to a compounding pharmacy. Some providers are uncomfortable prescribing compounded medications and prefer to prescribe FDA-approved brand products only.

Which is better, 503A or 503B compounded tirzepatide? 503B is generally better because 503B facilities are FDA-registered, follow cGMP manufacturing standards, and are required to test every batch for potency, sterility, and endotoxin levels. 503A pharmacies are state-licensed with variable oversight and are not required to perform batch testing by federal law (though some do).

Will insurance cover compounded tirzepatide? Usually not. Most insurance plans only cover FDA-approved medications. Compounded tirzepatide is not FDA-approved, so it's typically a cash-pay option. Some patients submit receipts for reimbursement, but approval is rare.

Can I buy tirzepatide from Canada or Mexico? Technically, but it's legally risky and safety is unverifiable. The FDA prohibits personal importation of prescription drugs except under narrow exceptions. Quality testing of international tirzepatide sources shows frequent contamination and incorrect dosing. U.S. compounded options are safer and only modestly more expensive.

What happens if the FDA removes tirzepatide from the shortage list? If tirzepatide is removed from the shortage list, 503A pharmacies can no longer legally compound it. 503B facilities can continue compounding because they're not restricted by the shortage list. Patients using 503A-compounded tirzepatide would need to switch to 503B-compounded or brand.

How do I know if a compounding pharmacy is legitimate? Check the FDA's Outsourcing Facility Database to verify 503B registration, verify the state pharmacy license through NABP, ask for certificates of analysis showing batch testing, and confirm the pharmacy requires a prescription. Avoid pharmacies that sell without prescriptions or won't provide testing documentation.

Can I use a GoodRx coupon for compounded tirzepatide? No. GoodRx and similar discount cards only work for FDA-approved medications dispensed by retail pharmacies. Compounded medications are not in the GoodRx network. Compounded pricing is set by the individual pharmacy or telehealth platform.

Is tirzepatide available as a generic? No. Tirzepatide's patent protection runs through 2036. FDA-approved generic tirzepatide will not be available until at least 2037. Compounded tirzepatide is not a generic; it's a compounded copy prepared under federal exemptions.

What's the cheapest way to get tirzepatide? If you have insurance that covers Mounjaro or Zepbound with a low copay ($25 to $75/month), that's cheapest. If you don't have coverage, compounded tirzepatide from a 503B facility at $300 to $400/month is cheapest among safe, legal options.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Patel R et al. Quality and Authenticity of Tirzepatide Products Purchased from International Online Pharmacies. JAMA Network Open. 2024.
4. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
5. U.S. Food and Drug Administration. Outsourcing Facilities Registered with FDA. Accessed April 2026.
6. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2025.
7. National Association of Boards of Pharmacy. PCAB Accreditation Standards. 2025.
8. IQVIA Institute for Human Data Science. Prescription Drug Coverage and Access Report. 2026.
9. American College of Gastroenterology. Obesity Management Guidelines. 2024.
10. Eli Lilly and Company. Mounjaro Prescribing Information. Updated 2026.
11. Eli Lilly and Company. Zepbound Prescribing Information. Updated 2026.
12. Davies MJ et al. Gastric Emptying and Satiety Responses to Tirzepatide. Diabetes Care. 2023.
13. U.S. Food and Drug Administration. Personal Importation Policy. CPG Sec. 610.200. Updated 2024.
14. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.